GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Pediatrix Medical Group Inc (NYSE:MD) » Definitions » Cash Conversion Cycle

Pediatrix Medical Group (Pediatrix Medical Group) Cash Conversion Cycle

: 42.87 (As of Dec. 2023)
View and export this data going back to 1959. Start your Free Trial

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Pediatrix Medical Group's Days Sales Outstanding for the three months ended in Dec. 2023 was 50.52.
Pediatrix Medical Group's Days Inventory for the three months ended in Dec. 2023 was 0.
Pediatrix Medical Group's Days Payable for the three months ended in Dec. 2023 was 7.65.
Therefore, Pediatrix Medical Group's Cash Conversion Cycle (CCC) for the three months ended in Dec. 2023 was 42.87.


Pediatrix Medical Group Cash Conversion Cycle Historical Data

The historical data trend for Pediatrix Medical Group's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pediatrix Medical Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 86.99 57.65 39.33 47.08 44.36

Pediatrix Medical Group Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Conversion Cycle Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 45.73 45.68 42.23 42.21 42.87

Competitive Comparison

For the Medical Care Facilities subindustry, Pediatrix Medical Group's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pediatrix Medical Group Cash Conversion Cycle Distribution

For the Healthcare Providers & Services industry and Healthcare sector, Pediatrix Medical Group's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Pediatrix Medical Group's Cash Conversion Cycle falls into.



Pediatrix Medical Group Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Pediatrix Medical Group's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=52.07+0-7.71
=44.36

Pediatrix Medical Group's Cash Conversion Cycle for the quarter that ended in Dec. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=50.52+0-7.65
=42.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pediatrix Medical Group  (NYSE:MD) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Pediatrix Medical Group Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Pediatrix Medical Group's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Pediatrix Medical Group (Pediatrix Medical Group) Business Description

Traded in Other Exchanges
Address
1301 Concord Terrace, Sunrise, FL, USA, 33323
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment, which is physician services. The company generates roughly half of its revenue from the women's and children's services provided, and also roughly half of the company's total revenue is earned in the United States.
Executives
James D Swift officer: EVP, Chief Operating Officer 1301 CONCORD TERRACE, SUNRISE FL 33323
Moore Mary Ann E officer: EVP Chief ERM/Legal Ops Off 1301 CONCORD TERRACE, SUNRISE FL 33323
Mark S Ordan director, officer: Chief Executive Officer 7315 WISCONSIN AVENUE, SUITE #250 WEST, BETHESDA MD 20814
Shirley A Weis director 11621 RESEARCH CIRCLE, GAINESVILLE FL 32615
Sylvia Jean Young director C/O LINCOLN EDUCATIONAL SERVICES CORPORA, 14 SYLVAN WAY, STE. A, PARSIPPANY NJ 07054
Lee Wood officer: EVP, Natl & Market Operations 1301 CONCORD TERRACE, SUNRISE FL 33323
Curtis Pickert officer: EVP, Chief Operating Officer 1301 CONCORD TERRACE, SUNRISE FL 33323
Laura A Linynsky director 1301 CONCORD TERRACE, SUNRISE FL 33323
Roger Md Medel director, officer: PRES. & CHIEF EXEC. OFFICER 1301 CONCORD TERRACE, SUNRISE FL 33323
John C Pepia officer: Principal Accounting Officer 1301 CONCORD TERRACE, SUNRISE FL 33323
Roger Mack Hinson officer: Pres., PDX & OBX Medical Group C/O MEDNAX, INC., 1301 CONCORD TERRACE, SUNRISE FL 33323
C Marc Richards officer: EVP, Chief Financial Officer 7315 WISCONSIN AVENUE, SUITE 250-W, BETHESDA MD 20814
Dominic J Andreano officer: Sr.VP,General Counsel & Secy. 1301 CONCORD TERRACE, SUNRISE FL 33323
Nicholas Nikolopoulos officer: EVP Chf Strategy & Growth Offi MEDNAX INC, 1301, SUNRISE FL 33323
Guy P Sansone director C/O MEDNAX, 1301 CONCORD TERRACE, SUNRISE FL 33323